Mrs
Dr
Miss
Ms
Prof
Printer Friendly
Printed from http://www.researchandmarkets.com/reports/1446125
Arisyn Therapeutics Inc. - Product Pipeline Review - Q4 2010
Description:
Arisyn Therapeutics Inc. – Product Pipeline Review – Q4 2010
Summary
Global Market Direct’s pharmaceuticals report, “Arisyn Therapeutics Inc. - Product Pipeline Review - Q4 2010” provides data on the company’s research and development focus. The report includes information on current developmental pipeline, complete with latest updates, and features on discontinued and dormant projects.
This report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company’s corporate website, SEC filings, investor presentations and featured press releases, both from company and industry-specific third party sources, put together by Global Markets Direct’s team.
Scope
- Arisyn Therapeutics Inc. - Brief company overview including business description, key information and facts, and its locations and subsidiaries.
- Review of current pipeline of Arisyn Therapeutics Inc. human therapeutic division.
- Overview of pipeline therapeutics across various therapy areas.
- Coverage of current pipeline molecules in various stages of drug development, including the combination treatment modalities, across the globe.
- Product profiles for late stage and clinical stage products of Arisyn Therapeutics Inc. with complete description of the product’s developmental history, mechanism of action, therapeutic class, target and major milestones.
- Recent updates of the Arisyn Therapeutics Inc.’s pipeline in the last quarter.
- Key discontinued and dormant projects.
- Latest news and deals relating to the products.
Reasons to buy
- Evaluate Arisyn Therapeutics Inc.’s strategic position with total access to detailed information on its product pipeline.
- Assess the growth potential of Arisyn Therapeutics Inc. in its therapy areas of focus.
- Identify new drug targets and therapeutic classes in the Arisyn Therapeutics Inc.’s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas.
- Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps.
- Exploit collaboration and partnership opportunities with Arisyn Therapeutics Inc..
- Avoid Intellectual Property Rights related issues.
- Explore the dormant and discontinued projects of Arisyn Therapeutics Inc. and identify potential opportunities in those areas.
Summary
Global Market Direct’s pharmaceuticals report, “Arisyn Therapeutics Inc. - Product Pipeline Review - Q4 2010” provides data on the company’s research and development focus. The report includes information on current developmental pipeline, complete with latest updates, and features on discontinued and dormant projects.
This report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company’s corporate website, SEC filings, investor presentations and featured press releases, both from company and industry-specific third party sources, put together by Global Markets Direct’s team.
Scope
- Arisyn Therapeutics Inc. - Brief company overview including business description, key information and facts, and its locations and subsidiaries.
- Review of current pipeline of Arisyn Therapeutics Inc. human therapeutic division.
- Overview of pipeline therapeutics across various therapy areas.
- Coverage of current pipeline molecules in various stages of drug development, including the combination treatment modalities, across the globe.
- Product profiles for late stage and clinical stage products of Arisyn Therapeutics Inc. with complete description of the product’s developmental history, mechanism of action, therapeutic class, target and major milestones.
- Recent updates of the Arisyn Therapeutics Inc.’s pipeline in the last quarter.
- Key discontinued and dormant projects.
- Latest news and deals relating to the products.
Reasons to buy
- Evaluate Arisyn Therapeutics Inc.’s strategic position with total access to detailed information on its product pipeline.
- Assess the growth potential of Arisyn Therapeutics Inc. in its therapy areas of focus.
- Identify new drug targets and therapeutic classes in the Arisyn Therapeutics Inc.’s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas.
- Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps.
- Exploit collaboration and partnership opportunities with Arisyn Therapeutics Inc..
- Avoid Intellectual Property Rights related issues.
- Explore the dormant and discontinued projects of Arisyn Therapeutics Inc. and identify potential opportunities in those areas.
Contents:
List of Tables
List of Figures
Arisyn Therapeutics Inc. Snapshot
Arisyn Therapeutics Inc. Overview
Key Information
Key Facts
Arisyn Therapeutics Inc. – Research and Development Overview
Key Therapeutic Areas
Arisyn Therapeutics Inc. – Pipeline Review
Pipeline Products by Stage of Development
Pipeline Products – Monotherapy
Arisyn Therapeutics Inc. – Pipeline Products Glance
Arisyn Therapeutics Inc. Clinical Stage Pipeline Products
Phase I Products/Combination Treatment Modalities
Arisyn Therapeutics Inc.–Early Stage Pipeline Products
Pre-Clinical Products/Combination Treatment Modalities
Arisyn Therapeutics Inc. – Drug Profiles
ATI 0917
Product Description
Mechanism of Action
R&D Progress
ATI-0312
Product Description
Mechanism of Action
R&D Progress
ATI 0607
Product Description
Mechanism of Action
R&D Progress
ATI 0655
Product Description
Mechanism of Action
R&D Progress
ATI 5488
Product Description
Mechanism of Action
R&D Progress
ATI-0409
Product Description
Mechanism of Action
R&D Progress
ATI-0810
Product Description
Mechanism of Action
R&D Progress
Arisyn Therapeutics Inc. – Pipeline Analysis
Arisyn Therapeutics Inc. – Pipeline Products by Therapeutic Class
Arisyn Therapeutics Inc. Pipeline Products By Target
Arisyn Therapeutics Inc. – Pipeline Products by Route of Administration
Arisyn Therapeutics Inc. – Pipeline Products by Molecule Type
Arisyn Therapeutics Inc. – Locations And Subsidiaries
Head Office
Recent Developments
Apr 21, 2009: ImQuest BioSciences Receives Phase I SBIR Grant To Develop A Novel Hepatitis C Virus Therapeutic Agent
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
Ordering:
Order Online - visit http://www.researchandmarkets.com/reports/1582661
Order by Fax - using the order form below
Order By Post - print the order form below and send to
Research and Markets,
Guinness Centre,
Taylors Lane,
Dublin 8,
Ireland.
Page 1 of 2
Printed Thursday, May 23, 2013
9:37:34 PM
9:37:34 PM
Fax order form
To place a fax order simply print this form, fill in and fax the completed form to the number below. If you have any questions please email help@researchandmarkets.net
Order information
Please verify that the product information is correct and select the format you require.
Product name
Arisyn Therapeutics Inc. - Product Pipeline Review - Q4 2010
Web Address
http://www.researchandmarkets.com/reports/1446125
Office Code
OC8DIQSNUONWTU
Report Formats
Please enter the quantity of the report format you require.
| Format | Quantity | Price | Electronic (PDF) - Single User |
|
EURO€ 384.00 |
|---|---|---|
| Electronic (PDF) - Site License |
|
EURO€ 769.00 |
| Electronic (PDF) - Enterprisewide |
|
EURO€ 1,153.00 |
Contact information
Please enter all the information below in block capitals.
Title:
Mr
Mrs
Dr
Miss
Ms
Prof
Mrs
Dr
Miss
Ms
Prof
First Name:
Last Name:
Email Address:
Job Title:
Organisation:
Address:
City:
Postal / Zip Code:
Country:
Phone Number:
Fax Number:
Please fax this form to:
(646) 607-1907 or (646) 964-6609 (from USA)
+353-1-481-1716 or +353-1-653-1571 (from Rest of World)
Page 2 of 2
Printed Thursday, May 23, 2013
9:37:34 PM
9:37:34 PM
Payment information
Please indicate the payment method you would like to use by selecting the appropriate box.
Pay by Credit Card:
American Express
Diners Club
Master Card
Visa
Cardholder's Name:
Cardholder's Signature:
Expiry Date:
/
Card Number:
CVV Security Code:
Issue date:
/ (Diners Club only)
Pay by Check:
Please post the check, accompanied by this form, to:
Research and Markets,
Guinness Centre,
Taylors Lane,
Dublin 8,
Ireland.
Pay by Wire Transfer:
Please transfer funds to:
Account Number:
83313083
Sort Code:
98-53-30
Swift Code:
ULSBIE2D
IBAN Number:
IE78ULSB98533083313083
Bank Address:
Ulster Bank,
27-35 Main Street
Blackrock,
Co. Dublin
Ireland.
27-35 Main Street
Blackrock,
Co. Dublin
Ireland.
If you have a Marketing Code please enter it below:
Marketing Code:
Please note that by ordering from Research and Markets you are agreeing to our Terms and Conditions at http://www.researchandmarkets.com/info/terms.asp